Navigation Links
Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
Date:1/26/2009

debt instruments that may be settled in cash upon conversion (including partial cash settlement) (FSP APB 14-1). Amgen expects the impact of the incremental non-cash interest expense associated with FSP APB 14-1 for 2009 to be in the range of $0.14 to $0.16 per share.

The company expects 2009 capital expenditures to be approximately $700 million.

Fourth Quarter Product and Pipeline Update

The Company provided updates on selected products and clinical programs.

Denosumab: The Company discussed the submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational RANK Ligand inhibitor. The indications for which Amgen is seeking FDA approval are treatment and prevention of postmenopausal osteoporosis (PMO) in women, and treatment and prevention of bone loss in patients undergoing hormone ablation for either prostate or breast cancer. The BLA submission contains data from six Phase 3 trials involving more than 11,000 patients. The Company has also submitted an application in Canada for these indications.

In the European Union, the Company has submitted an application for the approval of denosumab for treatment of PMO in women, and treatment of bone loss associated with hormone ablation therapy in patients with breast and prostate cancer.

Motesanib: The Company discussed the ongoing MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC). This trial was temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). The DMC also recommended that patients with squamous NSCLC immediately discontinue motesanib therapy but did not recommend discontinuation of motesanib therapy for patients with non-s
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Beckman Coulter Announces Fourth Quarter 2008 Earnings to be Released on Monday, February 9, 2009, After Market Closes
2. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
3. Caliper Life Sciences Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
4. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
5. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
6. BioMed Realty Trust Declares Fourth Quarter 2008 Common Stock and Preferred Stock Dividends
7. Martek Announces Fourth Quarter and FY 2008 Financial Results
8. Martek to Announce Fourth Quarter and Fiscal Year 2008 Results
9. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year
11. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 In preparation for VARTECH 2014, ... cybersecurity company focused on authentication and SSO announced today ... ability to generate a OTP through the presentation of ... of user-based RFID authentication, 2FA,s solutions have leveraged the ... many years. RFID authentication is broadly deployed in healthcare ...
(Date:9/16/2014)... 16, 2014 According to Jeff Howell, ... of ITRA Global, new development in Downtown Toronto is ... council approving another 755 storeys of new development last ... cranes will be dominating the Toronto skyline for the ... an unquenchable thirst for new development. , As the ...
(Date:9/15/2014)... solid, liquid, and gasbut much stranger things ... phase transitions occur at the coldest temperatures ... can dramatically transform a material. , ... Brookhaven National Laboratory and Stony Brook University ... zero to isolate and probe these quantum ...
(Date:9/15/2014)... Cancer Immunotherapy Market : ... Therapies is a new market research report announced ... principal types of therapeutics that have become the ... immunotherapy (which is often called "immuno-oncology") in recent ... cellular immunotherapy. , The regular use of ...
Breaking Biology Technology:2FA, Inc. Announces RFID-based One-Time Password (OTP) Authentication 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5
... eResearchTechnology, Inc. (ERT), (Nasdaq: ERT ) a ... to bio-pharmaceutical and healthcare organizations and the market leader ... drug development, announced today that its Board of Directors ... and Chief Executive Officer and as a member of ...
... Biopharmaceuticals, Inc. (NASDAQ: KERX ), a biopharmaceutical ... medically important pharmaceutical products for the treatment of cancer ... for the first quarter ended March 31, 2011. ... cash equivalents and investment securities of $23.1 million, as ...
... 2011 Frost & Sullivan Europe New Product Innovation Award ... for its state-of-the-art, high precision Novelda Impulse Radar transceiver ... Radar transceiver is a cutting-edge radar transceiver that incorporates ... unique penetration capabilities," remarks Frost & Sullivan Research Analyst ...
Cached Biology Technology:ERT Announces Appointment of New President and CEO 2ERT Announces Appointment of New President and CEO 3ERT Announces Appointment of New President and CEO 4Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results 4Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 2Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 3Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 4
(Date:9/16/2014)... PALM BEACH GARDENS, Fla. , Sept. 16, ... provider of biometric identity management solutions, announced today ... handheld solution designed to authenticate the identity of ... The Android-based Verifier Sentry rapidly reads ... the credential holder,s ID by matching the biometric ...
(Date:9/15/2014)... processes from digestion to disease resistance. Despite the fact ... on the planet, more is known about belly-button bacteria ... and colleagues working on Panama,s Barro Colorado Island discovered ... home to more than 400 different kinds of bacteria. ... than 7,000 different kinds. , Bacteria in tropical forests ...
(Date:9/15/2014)... has evolved a simple, mechanical solution to avoid ... 11 Science Express. , ... misalignments that lead to infertility, miscarriage, or congenital ... cause these problems, but what exactly goes wrong ... the Wellcome Trust Center for Cell Biology at ...
Breaking Biology News(10 mins):Cross Match Launches New Identity Management Handheld Solution 2Smithsonian scientists discover tropical tree microbiome in Panama 2Cells simply avoid chromosome confusion 2Cells simply avoid chromosome confusion 3
... go through a laboratory version of boot camp may ... of Pittsburgh researchers. In essence, that's the concept behind ... a patient's own souped up dendritic cells, which have ... system in fighting the virus unique to that individual. ...
... affiliate of Harvard Medical School, are the first to ... angiogenesis (new blood vessel growth). The switch, they learned, ... two enzymes (known as PI3K and PLCg) that compete ... fulfill opposite missions, growth and regression, respectively. This finding ...
... at the Harvard Department of Ophthalmology's Schepens Eye Research ... the first to learn why the cornea, the clear ... unique phenomenon that makes vision possible. The key, say ... of the protein VEGFR-3 (vascular endothelial growth factor receptor-3) ...
Cached Biology News:T cells activated to fight HIV basis for dendritic cell therapeutic vaccine 2T cells activated to fight HIV basis for dendritic cell therapeutic vaccine 3Schepens scientists are first to discover angiogenesis switch inside blood vessel cells 2Schepens scientists are first to discover angiogenesis switch inside blood vessel cells 3Scientists discover why cornea is transparent and free of blood vessels, allowing vision 2Scientists discover why cornea is transparent and free of blood vessels, allowing vision 3
Rabbit Anti-Mouse Ym1 Polyclonal Antibody,...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... of large numbers of samples may be carried ... which requires minimum operator attention. System control ... and interface CE 4900. The elegant, powerful ... Windows XP and Windows 98 and 2000., The ...
... This system uses the Adept CE 4100 ... Ultra-Fast Scanning UV/Visible detector for added flexibility and ... a trustworthy alternative to a photodiode array detection ... one detector is required for method development and ...
Biology Products: